Fig. 1



Sensitivity of Trough Plasma Imatinib Concentrations (%)
100
90
80
70
60
50
40
30
20
10
0
0
20
40
60
80
100
100 - specificity
AUC = 0.775

Fig. 2



Trough Plasma Imatinib Concentration (ng/ml)
3000
2500
2000
1500
1000
500
0
Without MMR
With MMR

Fig. 3



IRIS Study
4000
3000
2000
1000
0
ST571
Cmin (ng/mL)
1
51
101
151
201
251
301
351
Subj #

Fig. 4




Quartiles 2 and 3
≥ 647-1170 ng/mL
N = 178
Quartile 1
< 647 ng/mL
N = 87
Quartile 4
> 1170 ng/mL
N = 86
> 2000 ng/mL
(n = 19, included in Q4)
0
500
1000
1500
2000
Trough level (Day 29)

Fig. 5


Imatinib concentration (Day 29)
y= -3.523 *x + 1266 (R-square = 0.0149 )
Imatinib Cmin (ng/mL)
0
1000
2000
3000
4000
40
60
80
100
120
140
160
Body weight, kg at baseline




Imatinib concentration (Day 29)
y= -413 *x + 1763 (R-square = 0.0378 )
Imatinib Cmin (ng/mL)
0
1000
2000
3000
4000
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
Body surface area (m2) at baseline

Fig. 6


Estimated rate of CCyR (%)
100
90
80
70
60
50
40
30
20
10
0
0
12
24
36
48
60
Months since randomization to Imatinib
Category of Imatinib level
Q1
Q2-Q3
Q4



Estimated rate of MMR (%)
100
90
80
70
60
50
40
30
20
10
0
0
3
6
9
12
15
18
21
24
Months since randomization to Imatinib
Category of Imatinib level
Q1
Q2-Q3
Q4
86%
79%
63%
P = 0.03
(Q1 vs others)

Fig. 7





Fig. 8


100
90
80
70
% without event
60
50
40
30
20
10
0
0
12
24
36
48
Months since randomization to Imatinib
Category of Imatinib lev
Q1
Q2- Q3
Q4
P- 0.(16 overall